Clinical trial
3-AP and Cisplatin in Treating Patients With Recurrent or Persistent…
NCT00081276 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00081276 |
|---|---|
| Title | 3-AP and Cisplatin in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer |
| Official title | A Phase II Evaluation Of Triapine (NCI-Supplied Agent: NSC #663249, IND #68338) In Combination With Cisplatin (Commercially Available: NSC # 119875) In The Treatment Of Recurrent Or Persistent Platinum-Resistant Ovarian Or Primary Peritoneal Carcinoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer |
| Intervention type | Drug, Other |
| Interventions | triapine, cisplatin, laboratory biomarker analysis |
| Enrollment | 48 |
| Start date | Jul 1, 2005 |
| Primary completion | Jan 1, 2007 |
| First posted | Apr 8, 2004 |
| Last update posted | Jan 24, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: